Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026
Same author

Identification, reliability, and validity of drug-drug interaction checkers in chronic diseases: A systematic review.

British journal of pharmacology·2026
Same author

The role of premorbid cognitive performance in the neuropsychological assessment of people with HIV in South Africa.

PloS one·2026
Same author

How pharmacokinetic/pharmacodynamic models can inform the development of new HIV medications.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
Same author

Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).

The Lancet. Microbe·2026
Same author

Brain Structure of South African Children Born to Mothers on Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy.

Journal of the Pediatric Infectious Diseases Society·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Grapefruit-drug interactions.

Kay Seden1, Laura Dickinson, Saye Khoo

  • 1NIHR Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK. k.seden@liv.ac.uk

Drugs
|December 15, 2010
PubMed
Summary
This summary is machine-generated.

Grapefruit juice interacts with medications by inhibiting cytochrome P450 3A4 and transporters, affecting drug bioavailability. Understanding these grapefruit-drug interactions is crucial for patient safety.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jun 6, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Nutritional Science

Background:

  • Grapefruit consumption offers health benefits but can cause significant drug interactions.
  • These interactions primarily involve inhibition of intestinal cytochrome P450 3A4 (CYP3A4) and drug transporters.
  • Furanocoumarins and flavonoids are implicated as key compounds responsible for these interactions.

Purpose of the Study:

  • To elucidate the mechanisms underlying grapefruit-drug interactions.
  • To summarize drugs affected by grapefruit consumption.
  • To assess the clinical relevance of these interactions.

Main Methods:

  • Review of existing literature on grapefruit-drug interactions.
  • Analysis of mechanisms involving CYP3A4 inhibition and transporter interactions (P-glycoprotein, OATPs).
  • Evaluation of factors influencing interaction magnitude, including furanocoumarin/flavonoid concentrations and patient variability.

Main Results:

  • Grapefruit compounds inhibit CYP3A4, increasing bioavailability of substrate drugs like calcium channel blockers, immunosuppressants, and antihistamines.
  • Interactions with P-glycoprotein and organic anion-transporting polypeptides (OATPs) are mediated by polyphenolic compounds.
  • Predicting interaction extent is complex due to variable concentrations, consumption volumes, and individual human variability.

Conclusions:

  • Grapefruit-drug interactions are mediated by furanocoumarins and flavonoids affecting key drug-metabolizing enzymes and transporters.
  • The clinical significance varies based on the drug's properties and patient factors.
  • Further research is needed to accurately predict and manage these interactions.